Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Dianthus Therapeutics, Inc. - Common Stock
(NQ:
DNTH
)
28.30
+0.68 (+2.46%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
122,232
Open
27.99
Bid (Size)
28.32 (2)
Ask (Size)
28.41 (5)
Prev. Close
27.62
Today's Range
27.84 - 28.90
52wk Range
6.580 - 33.77
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Navigating 4 Analyst Ratings For Dianthus Therapeutics
August 12, 2024
Via
Benzinga
DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 09, 2024
DNTH stock results show that Dianthus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Performance
YTD
+147.16%
+147.16%
1 Month
+0.75%
+0.75%
3 Month
+29.11%
+29.11%
6 Month
+11.07%
+11.07%
1 Year
+157.27%
+157.27%
More News
Read More
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
August 08, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)
June 28, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
What 5 Analyst Ratings Have To Say About Dianthus Therapeutics
May 10, 2024
Via
Benzinga
What 5 Analyst Ratings Have To Say About Dianthus Therapeutics
April 18, 2024
Via
Benzinga
Decoding 4 Analyst Evaluations For Dianthus Therapeutics
February 15, 2024
Via
Benzinga
Why Dianthus Therapeutics (DNTH) Stock Is Exploding Higher
January 22, 2024
Via
Benzinga
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)
June 12, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024
May 09, 2024
Via
InvestorPlace
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
May 09, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
May 08, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
April 11, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 22, 2024
Via
Benzinga
Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday
March 22, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q4 2023
March 21, 2024
Via
InvestorPlace
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 07, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)
February 26, 2024
From
Dianthus Therapeutics, Inc.
Via
GlobeNewswire
DNTH Stock Earnings: Dianthus Therapeutics Reported Results for Q3 2023
December 14, 2023
Via
InvestorPlace
Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst
November 22, 2023
Via
Benzinga
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
September 28, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023
September 28, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.